According to recent filing news Novan (NOVN) has filed a patent for topical antivrial compositions and methods to prevent viral infections which is most likely related to the COVID-19 coronavirus pandemic.
The filing states the present invention relates generally to topical antiviral compositions for use in a method of treating and/or preventing a viral infection.
Viruses cause a number of diseases that can be treated topically. For example, warts can be caused by human papillomavirus and can be treated topically.
However, viruses can be difficult to treat since they invade host cells and
replicate. In addition, new viral strains have emerged, including antiviral resistant strains.
The filing also states that the embodiment will may be incorporated in different ways. According to the document, the viruses it may treat or prevent are but not limited to viral infection caused by cytomegalovirus (CMV), epstein-barr virus, varicella zoster virus (VZV), vaccinia virus, cowpox virus, monkeypox virus, herpes simplex virus (HSV 1+2), herpes zoster, human herpes virus 6 (HHV-6), human herpes virus 8 (HHV-8), papillomavirus, molluscum contagiosum, orf, variola, and/or coxsackie virus.
In some embodiments, the viral infection may be caused by a apillomavirus, such as a human papillomavirus. The human papillomavirus (HPV) may be HPV type 1, 2, 3, 4, 6, 10, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and/or 59.
According to more information displayed by the document, it may also treat and/or prevent other infectious diseases too, as shown in the image below.
Novan (NOVN): Finding examples of methods
It’s stated that Nitricil™ NVN1 was effective in treating both wild type virus and the mutant strain with complete inhibition of papilloma growth in the mutant strain and substantial separation between treated and untreated sites in the faster growing wild type. It shows that 16.3% Nitricil™ NVN4 was effective at inhibiting growth of the mutant strain but was not effective
at inhibiting growth of the wild type virus.
It shows that the ointment vehicle without a NO-releasing API provided little to no separation in papilloma size between the treated and untreated sites for either the wild type or mutant papilloma virus sites.
The document also shows that the 10% NVN1 ointment provided little to no separation in papilloma size between the treated and untreated sites for either the wild type or mutant papilloma virus sites, illustrating the release of nitric oxide from the composition affects the effectiveness of inhibiting papilloma growth, as opposed to the presence of the siloxane backbone as the 10% NVN1 ointment and the 10% NVN1 gel both contained the same amount of the polysiloxane backbone but achieved markedly different results.
Novan (NOVN): Should you buy or sell now?
It is recommended that you should definitely buy, shares of Novan appear to be a very good investment option, with Wall Street analysts expecting its price to rise considerably in the next several months. The majority of the metrics point to this investment being highly attractive investment.
